Last reviewed · How we verify
NCT06006741
Universal CAR-T Cells Targeting Multiple Myeloma
Phase 1 trial testing MM-specific universal CAR T cells in Multiple Myeloma in Remission in 20 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Shenzhen Geno-Immune Medical Institute |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 31 October 2023 |
| Primary completion | 30 September 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- MM-specific universal CAR T cells — full drug profile →
Conditions studied
- Multiple Myeloma in Remission — all drugs for Multiple Myeloma in Remission →
Sponsor
Shenzhen Geno-Immune Medical Institute
Who can join
Adults 18 to 80, any sex, with Multiple Myeloma in Remission. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to assess the feasibility, safety and efficacy of universal CAR T cells targeting multiple myeloma. Another goal of the study is to learn more about the persistence and function of the universal CAR T cells in the body.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
Lu Q, Li H, Wu Z, Zhu Z, et al · · 2024 · cited 11× · PMID 38783333 · DOI 10.1186/s12951-024-02512-6 -
Targeted therapy for multiple myeloma: an overview on CD138-based strategies.
Riccardi F, Tangredi C, Dal Bo M, Toffoli G. · · 2024 · cited 9× · PMID 38655136 · DOI 10.3389/fonc.2024.1370854 -
A structural, genetic and clinical comparison of CAR-T cells and CAR-NK cells: companions or competitors?
Andrea AE, Chiron A, Sarrabayrouse G, Bessoles S, et al · · 2024 · cited 8× · PMID 39430751 · DOI 10.3389/fimmu.2024.1459818 -
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Verify or expand the search:
- PubMed search for NCT06006741
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Shenzhen Geno-Immune Medical Institute trials
Trials by the same sponsor.
- NCT07501156 — H3K27M-specific Immune Effector Cells Targeting DMG/DIPG · Phase 1, PHASE2 · recruiting
- NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
- NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
- NCT07180927 — DLL3 CAR-T Therapy Targeting Brain Tumors · Phase 1, PHASE2 · recruiting
- NCT07193966 — NG2 and DLL3 CAR-T Cells Targeting Melanoma · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06006741 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shenzhen Geno-Immune Medical Institute
- Last refreshed: 12 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06006741.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing